LIGAND PHARMACEUTICALS INC Quarterly Operating Income (Loss) in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Ligand Pharmaceuticals Inc quarterly/annual Operating Income (Loss) history and growth rate from Q2 2010 to Q3 2024.
  • Ligand Pharmaceuticals Inc Operating Income (Loss) for the quarter ending September 30, 2024 was $3.14M, a 2.11% increase year-over-year.
  • Ligand Pharmaceuticals Inc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$16.3M, a 240% decline year-over-year.
  • Ligand Pharmaceuticals Inc annual Operating Income (Loss) for 2023 was $11.9M, a 293% increase from 2022.
  • Ligand Pharmaceuticals Inc annual Operating Income (Loss) for 2022 was $3.04M, a 97.1% decline from 2021.
  • Ligand Pharmaceuticals Inc annual Operating Income (Loss) for 2021 was $104M, a 177% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$16.3M $3.14M +$65K +2.11% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 -$16.4M -$19.1M -$17.1M -863% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $725K $2.99M -$11.2M -79% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $11.9M -$3.36M +$16.7M +83.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 -$4.8M $3.08M -$9.26M -75.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 $4.46M -$1.98M -$10.6M -123% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $15.1M $14.2M +$12.1M +566% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $3.04M -$20.1M -$57.8M -153% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $60.8M $12.3M -$3.37M -21.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $64.2M $8.66M -$37.1M -81.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $101M $2.13M -$2.58M -54.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $104M $37.7M +$14.8M +64.8% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 $89M $15.7M +$12M +319% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $77.1M $45.7M +$38.6M +544% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $38.4M $4.72M +$927K +24.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $37.5M $22.9M +$33M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $4.46M $3.75M +$8.91M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$4.45M $7.1M +$11.2M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$15.7M $3.79M -$823M -99.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $807M -$10.2M -$43.3M -131% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $850M -$5.16M -$28.5M -122% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $879M -$4.13M -$74.3M -106% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $953M $827M +$790M +2131% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $164M $33.1M +$4.8M +16.9% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-24
Q3 2018 $159M $23.4M +$6.87M +41.6% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $152M $70.2M +$57.2M +439% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $94.9M $37M +$26.8M +263% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $68.1M $28.4M +$9M +46.5% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 $59.1M $16.5M +$11M +202% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $48.1M $13M +$9.05M +228% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 $39M $10.2M -$4.88M -32.3% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $43.9M $19.4M +$8.34M +75.7% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-28
Q3 2016 $35.5M $5.47M -$3.13M -36.4% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $38.7M $3.97M -$396K -9.07% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $39.1M $15.1M +$11.7M +351% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 $27.3M $11M +$1.38M +14.3% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-01
Q3 2015 $25.9M $8.6M +$5.07M +143% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-15
Q2 2015 $20.9M $4.37M +$3.01M +221% Apr 1, 2015 Jun 30, 2015 10-Q/A 2016-11-15
Q1 2015 $17.9M $3.35M -$1.75M -34.3% Jan 1, 2015 Mar 31, 2015 10-Q/A 2016-11-15
Q4 2014 $19.6M $9.64M +$3.21M +49.9% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-28
Q3 2014 $16.4M $3.53M +$462K +15% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-09
Q2 2014 $16M $1.36M -$156K -10.3% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-05
Q1 2014 $16.1M $5.1M +$1.17M +29.7% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-11
Q4 2013 $14.9M $6.43M +$2.16M +50.4% Oct 1, 2013 Dec 31, 2013 10-K/A 2016-11-15
Q3 2013 $12.8M $3.07M +$4.5M Jul 1, 2013 Sep 30, 2013 10-Q 2014-10-31
Q2 2013 $8.29M $1.51M +$3.33M Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-05
Q1 2013 $4.96M $3.93M +$4.77M Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-07
Q4 2012 $193K $4.27M -$392K -8.41% Oct 1, 2012 Dec 31, 2012 10-K 2015-02-23
Q3 2012 $585K -$1.43M +$1.82M +56.1% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-08
Q2 2012 -$1.24M -$1.82M -$1.01M -124% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-01
Q1 2012 -$234K -$839K +$644K +43.4% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-08
Q4 2011 -$878K $4.66M Oct 1, 2011 Dec 31, 2011 10-K/A 2014-12-12
Q3 2011 -$3.25M +$12.4M +79.3% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-14
Q2 2011 -$810K +$2.82M +77.7% Apr 1, 2011 Jun 30, 2011 10-Q/A 2012-11-14
Q1 2011 -$1.48M Jan 1, 2011 Mar 31, 2011 10-Q/A 2012-11-14
Q3 2010 -$15.7M Jul 1, 2010 Sep 30, 2010 10-Q/A 2012-02-10
Q2 2010 -$3.63M Apr 1, 2010 Jun 30, 2010 10-Q/A 2012-02-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.